Abstract
Individuals with neurological disease or injury such as amyotrophic lateral sclerosis, spinal cord injury or stroke may become tetraplegic, unable to speak or even locked-in. For people with these conditions, current assistive technologies are often ineffective. Brain-computer interfaces are being developed to enhance independence and restore communication in the absence of physical movement. Over the past decade, individuals with tetraplegia have achieved rapid on-screen typing and point-and-click control of tablet apps using intracortical brain-computer interfaces (iBCIs) that decode intended arm and hand movements from neural signals recorded by implanted microelectrode arrays. However, cables used to convey neural signals from the brain tether participants to amplifiers and decoding computers and require expert oversight during use, severely limiting when and where iBCIs could be available for use. Here, we demonstrate the first human use of a wireless broadband iBCI. Based on a prototype system previously used in pre-clinical research, we replaced the external cables of a 192-electrode iBCI with wireless transmitters and achieved high-resolution recording and decoding of broadband field potentials and spiking activity from people with paralysis. Two participants in an ongoing pilot clinical trial performed on-screen item selection tasks to assess iBCI-enabled cursor control. Communication bitrates were equivalent between cabled and wireless configurations. Participants also used the wireless iBCI to control a standard commercial tablet computer to browse the web and use several mobile applications. Within-day comparison of cabled and wireless interfaces evaluated bit error rate, packet loss, and the recovery of spike rates and spike waveforms from the recorded neural signals. In a representative use case, the wireless system recorded intracortical signals from two arrays in one participant continuously through a 24-hour period at home. Wireless multi-electrode recording of broadband neural signals over extended periods introduces a valuable tool for human neuroscience research and is an important step toward practical deployment of iBCI technology for independent use by individuals with paralysis. On-demand access to high-performance iBCI technology in the home promises to enhance independence and restore communication and mobility for individuals with severe motor impairment.
Competing Interest Statement
The Massachusetts General Hospital (MGH) Translational Research Center has a clinical research support agreement with Neuralink, Paradromics, and Synchron, for which LRH provides consultative input. KVS is a consultant to Neuralink Inc., and on the Scientific Advisory Boards of CTRL-Labs, Inscopix Inc., Heal Inc. and Mind X. JMH is a consultant for Neuralink Corp., Proteus Biomedical and Boston Scientific, and serves on the Medical Advisory Boards of Enspire DBS and Circuit Therapeutics.
Clinical Trial
NCT00912041
Funding Statement
This work was supported in part by NIH-NINDS UH2NS095548; the Office of Research and Development, Rehab. R&D Service, Department of Veterans Affairs (N9228C, N2864C, A2295R, B6453R, P1155R); NIH-NIDCD R01DC009899 and R01DC014034; NIH-NBIB R01EB007401; The Executive Committee on Research (ECOR) of Massachusetts General Hospital; MGH-Deane Institute; DARPA REPAIR; Wu Tsai Neurosciences Institute at Stanford; Larry and Pamela Garlick; Samuel and Betsy Reeves; The Howard Hughes Medical Institute; Conquer Paralysis Now 004698.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The sharing of the human neural data is restricted due to the potential sensitivity of this data. Data may be made available upon request to the authors (J.D.S. or L.R.H.). To respect the participants’ expectation of privacy, a legal agreement between the researcher's institution and the BrainGate consortium would need to be set up to facilitate any sharing of these datasets.